GYRE THERAPEUTICS, INC. GYRE

Latest FY: 2025 Healthcare Biotechnology
Market Price $6.76
Market Cap $655.91M
P/E Ratio 338.00
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑10.2% YoY
$116.59M
3-Yr CAGR: 427.6%
Net Income ↓-44.8% YoY
$9.88M
Net Margin: 8.5%
Free Cash Flow ↑97.0% YoY
-$180.00K
FCF Yield: -0.03%
EPS (Diluted) ↓-60.0% YoY
$0.02
Basic: $0.06
Return on Equity Efficiency
9.3%
ROA: 5.9%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (GYRE)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $-11.2M $-16.9M $-21.75 0.00% $-18.5M $-18.9M
FY 2017 $1.0M $-11.8M $-21.6M -27.2% 0.00% $-19.9M $-20.0M -5.4%
FY 2018 $0.0M -99.4% $-21.5M $-30.1M -39.4% 0.00% $-28.6M $-28.9M -44.9%
FY 2019 $2.1M +35,650.0% $-43.9M $-55.2M -83.6% 0.00% $-43.6M $-43.7M -51.0%
FY 2020 $20.9M +876.6% $11.8M $-56.2M -1.9% 0.00% $-55.0M $-55.3M -26.6%
FY 2021 $7.3M -65.0% $-0.0M $-87.9M -56.4% 0.00% $-83.8M $-84.6M -52.9%
FY 2022 $0.8M -89.2% $-0.0M $-8.2M +90.6% $-0.26 $0.24 3.02% $-33.1M $-33.8M +60.0%
FY 2023 $113.5M +14,188.4% $108.8M $-85.5M -937.1% $-1.41 -442.3% 0.00% $25.9M $17.4M +151.4%
FY 2024 $105.8M -6.8% $101.9M $17.9M +120.9% $0.05 +103.5% 0.00% $-3.6M $-6.0M -134.3%
FY 2025 $116.6M +10.2% $111.2M $9.9M -44.8% $0.02 -60.0% 0.00% $1.0M $-0.2M +97.0%
$

Valuation

Market Price $6.76
Market Cap $655.91M
Enterprise Value $618.84M
P/E Ratio 338.00
P/B Ratio 6.19
FCF Yield -0.03%
Dividend Yield 3.55%
Shares Outstanding 97,028,300
%

Profitability & Margins

Gross Margin 95.35%
Operating Margin 9.85%
Net Margin 8.47%
Return on Equity (ROE) 9.32%
Return on Assets (ROA) 5.95%
Asset Turnover 0.70x
Revenue 3-Yr CAGR 427.57%
🛡️

Financial Health & Liquidity

Current Ratio 5.60
Cash Ratio 2.03
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $37.07M
Total Debt N/A
Book Value / Share $1.09
💧

Cash Flow Efficiency

Operating Cash Flow $1.01M
Capital Expenditures (CapEx) $1.19M
Free Cash Flow -$180.00K
OCF / Revenue 0.87%
FCF / Revenue -0.15%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $0.02
EPS (Basic) $0.06
Dividends / Share $0.24
Book Value / Share $1.09
EPS YoY Growth -60.00%
🏛️

Balance Sheet (FY 2025)

Total Assets $166.13M
Total Liabilities $60.10M
Stockholders' Equity $106.03M
Current Assets $102.37M
Current Liabilities $18.29M